GlassScriptPhysician profile
Oladipo Kusemiju
NPI 1215164769
$2,575.86
in general payments reported to CMS, 2019-2025
32 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219 · 2020: $212 · 2021: $271 · 2022: $229 · 2023: $663 · 2024: $692 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,644.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $461.90 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $371.23 | 2021-2024 | |
| Lilly USA, LLC | $205.98 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $191.16 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $157.80 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $122.49 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.47 | 2019-2021 | |
| Exact Sciences Corporation | $115.38 | 2023-2025 | Cologuard Collection Kit |
| Vertos Medical, INC. | $109.85 | 2024 | Mild Device Kit |
| Glaxosmithkline, LLC. | $89.84 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Astellas Pharma US INC | $67.07 | 2020-2025 | Veozah |
| Amarin Pharma, INC. | $54.53 | 2019-2021 | |
| Amgen INC. | $45.35 | 2021-2025 | Repatha, Otezla, Repatha |
| Dexcom, INC. | $43.03 | 2023-2025 | Dexcom G6 Transmitter |
| Teva Pharmaceuticals USA, INC. | $43.01 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $40.82 | 2025 | Contrave, Onzetra Xsail |
| Takeda Pharmaceuticals U.S.A., INC. | $36.94 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $28.97 | 2021 | |
| Sanofi Pasteur INC. | $27.34 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.14 | 2024 | Xifaxan |
| Painteq LLC | $26.14 | 2024 | Painteq |
| Dynavax Technologies Corporation | $24.51 | 2024 | Heplisav-B |
| Sunovion Pharmaceuticals INC. | $23.03 | 2020 | |
| Sumitomo Pharma America, INC. | $22.18 | 2025 | Myfembree |
| Neurocrine Biosciences, INC. | $20.43 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.01 | 2021 | |
| Merck Sharp & Dohme LLC | $18.60 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
| Phadia US INC. | $15.50 | 2025 | Immunocap |
| Mylan Specialty L.P. | $13.73 | 2019 | |
| Ironshore Pharmaceuticals INC. | $13.41 | 2019 | |
| Allergan, INC. | $11.03 | 2020 | |
| Supernus Pharmaceuticals, INC. | $10.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oladipo Kusemiju listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.